Wednesday preview: Glaxo, ARM, BATS, Capita, GDP

GlaxoSmithline's second quarter update should see the group just about manage to increase revenue year-on-year if the analyst community following the pharmaceuticals colossus is on the money.

GlaxoSmithline's second quarter update should see the group just about manage to increase revenue year-on-year if the analyst community following the pharmaceuticals colossus is on the money.

Second quarter revenue is tipped to rise to £6,750m from £6,720m a year earlier, while core operating profit is forecast to rise to £2,153m from £2,071m in the second quarter of 2011.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up
Latest Videos FromMoneyWeek
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.